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Background: The effectiveness of strategies for treatment of the altered static lung volume and against the
development of bronchial hyperreactivity (BHR) following a left ventricular dysfunction (LVD) induced by myocardial
ischaemia was investigated in a rat model of sustained postcapillary pulmonary hypertension.
Methods: Airway resistance (Raw) was identified from the respiratory system input impedance (Zrs) in four groups
of rats. End-expiratory lung volume (EELV) was determined plethysmographically, and Zrs was measured under
baseline conditions and following iv infusions of 2, 6 or 18 μg/kg/min methacholine. Sham surgery was performed
in the rats in Group C, while the left interventricular coronary artery was ligated and Zrs and its changes following
identical methacholine challenges were reassessed in the same rats 8 weeks later, during which no treatment was
applied (Group I), or the animals were treated daily with a combination of an angiotensin enzyme converter
inhibitor and a diuretic (enalapril and furosemide, Group IE), or a calcium channel blocker (diltiazem, Group ID). The
equivalent dose of methacholine causing a 100% increase in Raw (ED50) was determined in each group. Diastolic
pulmonary arterial pressure (PapD) was assessed by introducing a catheter into the pulmonary artery.
Results: The sustained presence of a LVD increased PapD in all groups of rats, with variable but significant
elevations in Groups I (p = 0.004), ID (p = 0.013) and IE (p = 0.006). A LVD for 8 weeks induced no changes in
baseline Raw but elevated the EELV independently of the treatments. In Group I, BHR consistently developed
following the LVD, with a significant decrease in ED50 from 10.0 ± 2.5 to 6.9 ± 2.5 μg/kg/min (p = 0.006). The BHR
was completely abolished in both Groups ID and IE, with no changes in ED50 (9.5 ± 3.6 vs. 10.7 ± 4.7, p = 0.33 and
10.6 ± 2.1 vs. 9.8 ± 3.5 μg/kg/min p = 0.56, respectively).
Conclusions: These findings suggest that a LVD following coronary ischaemia consistently induces BHR. The more
consistent efficacy of both treatment strategies in preventing BHR than in treating the adverse pulmonary vascular
consequences suggests the benefit of both calcium channel blockade and ACE inhibition to counteract the airway
susceptibility following a LVD.Background
The results of previous clinical and experimental studies
clearly established that a left ventricular dysfunction
(LVD) leads to a lung function impairment manifested
in airflow limitation and compromised lung compliance
[1,2]. There is also increasing evidence that the dimin-
ished airway function following a LVD results in the de-
velopment of bronchial hyperreactivity (BHR) in
response to exogenous constrictor stimuli [1,3-5]. The
pulmonary congestion subsequent to chronic LVD in* Correspondence: petak@dmi.szote.u-szeged.hu
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reproduction in any medium, provided the orpatients advances the development of clinical symptoms,
such as wheezing, coughing, dyspnea and recurrent
bronchospasm triggered by exposures to various provo-
cation agonists [1,4]. A number of factors may contrib-
ute to the development of BHR following a LVD,
including a decrease in airway cross-sectional area [6]
due to the compression of the airways by the dilated pul-
monary vessels [4], an elevated capillary hydrostatic
pressure leading to mucosal swelling [1,3], and airway
wall hypertrophy [7].
In clinical practice, different treatment strategies are
considered in the presence of LVD in order to improve
the cardiac output, to advance fluid clearance and to de-
crease pulmonary congestion. Angiotensin convertingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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first-line therapy through which to counteract the renin-
angiotensin pathway and hence the production and se-
cretion of aldosterone [8], with an ultimate reduction of
the systemic vascular resistance and relief of the vascular
engorgement. Alternatively, there has been some interest
in the blockade of calcium entry, which can potentially
improve the left ventricular function via systemic arterial
vasodilation, leading to a reduced ventricular afterload,
reflex activation of the sympathetic nervous system and
direct improvement of the myocardial inotropic depres-
sion [9,10]. Despite these well-established beneficial
effects of these treatments on the haemodynamic out-
comes, there have been no studies aimed at establishing
how these treatment strategies ultimately alter the ad-
verse pulmonary consequences of a LVD. Accordingly,
the effectiveness of such treatments as concerns the
alterations in the basal airway and tissue mechanical
properties, lung volume and airway responsiveness has
not been characterized.
We therefore set out to explore the pulmonary conse-
quences of these common treatment strategies, applied
in the presence of a sustained elevation in pulmonary
venous pressure following the induction of a LVD in a
well-established experimental model [11] mimicking the
adverse pulmonary symptoms of chronic lung conges-
tion. Changes in pulmonary haemodynamics, basal air-
way and tissue mechanics and lung responsiveness were
characterized following a decrease in the insult from the
vascular remodelling by i) an ACE inhibitor combined
with a diuretic and ii) a calcium channel blocker.
Methods
Animal preparations
The experimental protocol was approved by the Experi-
mental Ethics Committee of the University of Geneva
(No. 09-45) and the Animal Welfare Committee of the
Canton of Geneva (No. 1051/3542/3). On the experi-
mental days, adult male Sprague–Dawley rats (initially
weighing 342-395 g) were anaesthetized by the intraperi-
toneal injection of chloral hydrate (350 mg/kg). Tracheal
intubation was achieved with a polyethylene cannula
(16-gauge, Braun, Melsungen, Germany) and the rats
were allowed to breathe spontaneously for the lung vol-
ume measurement. The rats were then mechanically
ventilated with a tidal volume of 7 ml/kg body weight, a
positive end-expiratory pressure of 2.5 cmH2O, and a re-
spiratory rate of 60-70/min (constant volume-cycled ro-
dent ventilator, model 683, Harvard Apparatus Co Inc.,
South Natick, MA, USA). After the completion of
plethysmography, the femoral vein was cannulated and a
continuous iv infusion of midazolam (1 mg/kg/h) with
fentanyl (40 μg/kg/h) and atracurium (1 mg/kg/h) was
administered to ensure an adequate anaesthesia andanalgesia level throughout the study. The femoral artery
was cannulated (Abocath 22 G) and attached to a pres-
sure transducer (Model 156 PCE 06-GW2, Honeywell,
Zürich, Switzerland) for continuous blood pressure
monitoring. An arterial line was also used for blood gas
analysis (Model 505, Acid Base Laboratory, Copenhagen,
Denmark). The airway pressure, arterial pressure, ECG
and rectal temperature were continuously monitored by
a data collection and acquisition system (Biopac, Santa
Barbara, CA, USA).
Surgical preparations for the induction of LVD
An additional bolus of fentanyl was administered intra-
arterially (15 μg/kg) to strengthen the level of analgesia.
The heart in each rat was then surgically exposed by a
left lateral thoracotomy (5th intercostal). A prophylactic
dose of lidocaine (2 mg/kg intra-arterially) was adminis-
tered to prevent arrhythmias that may arise from
ligation of the coronary artery. After opening of the peri-
cardium, a silk thread was sutured around the proximal
part of the descending interventricular coronary artery
(next to the departure of the pulmonary artery).
Treatments and protocol groups
In the animals assigned to Groups I (n = 10), ID (n = 9)
and IE (n = 10), the knot was tightened to induce a LVD
via myocardial ischaemia, while in the rats enrolled in
Group C (n = 10), sham surgery was performed by re-
moval of the silk thread without occlusion of the coron-
ary artery. The thorax was closed after removing the
residual air in the pleural cavity, and a long-acting local
anaesthetic (bupivacaïne 0.25%, 0.8-1.2 ml) was infil-
trated around the surgical wounds. 0.5 mg/kg of bupre-
norphine (TemgesicW) was injected subcutaneously
before the rat was allowed to recover from the anaesthe-
sia, and this dose was repeated 18 h later to ensure ad-
equate analgesia.
After creation of the LVD, the animals were rando-
mized to be included to receive no further treatment
during the 8-week study period (Group I), regular treat-
ment with a calcium channel blocker (diltiazem 10 mg/
kg/day via daily ip injection) for 8 weeks (Group ID), or
regular treatment with an ACE inhibitor (enalapril,
10 mg/kg/day, via oral gavage) supplemented with a di-
uretic (furosemide 2 mg/kg/day, via oral gavage) until
the next experimental day 8 weeks later (Group IE). The
daily itraperitoneal and oral treatments were performed
by gentle restraining of the animals without sedation.
The route of administration of the treatment agents and
the doses were chosen on the basis of their pharmacoki-
netic properties and the manufacturers’ recommenda-
tions. Eight weeks after the completion of the first part
of the investigations, the animals were re-evaluated as
detailed above, and the second part of the investigations
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Measurements of end-expiratory lung volume (EELV)
After the anaesthesia with chloral hydrate and the surgi-
cal preparations, the measurements of EELV were per-
formed in all groups by using a body plethysmograph, as
detailed earlier [12]. Briefly, the trachea was occluded at
end-expiration until 3 or 4 spontaneous inspiratory
efforts had been generated by the animal in the closed
box. The changes in tracheal pressure and plethysmo-
graph box pressure during these manoeuvres were
recorded, and EELV was calculated by applying Boyle's
law to the relationship between the tracheal pressure and
the box pressure after correction for the box impedance
[13]. The recordings of box pressure were corrected for
the thermal characteristics of the plethysmograph [13];
this minimized the biasing effects of the different breath-
ing frequencies during the inspiratory efforts. The suffi-
cient spontaneous breathing manoeuvres were required
for the measurement of EELV were not always achieved
in the anaesthetized animals: these measurements were
successfully accomplished in 8, 7, 9 and 10 animals in
Groups C, I, ID and IE, respectively.
Forced oscillatory measurements
The contributions of the airway and tissue mechanical
properties to the total respiratory resistance were
assessed by the forced oscillation technique in the
anesthetized animals through measurement of the mech-
anical impedance of the respiratory system (Zrs), as
described in detail previously [14,15]. Briefly, the tra-
cheal cannula was connected from the respirator to a
loudspeaker-in-box system at end-expiration. Zrs was
measured with the wave-tube technique by introducing
pseudorandom forced oscillations at frequencies be-
tween 0.5 and 21 Hz at end-expiration. Two identical
pressure transducers (Model 33NA002D, ICSensors,
Malpitas, CA, USA) were used to measure the lateral
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Figure 1 Scheme of the experimental protocol.the wave-tube, and Zrs was calculated as the load im-
pedance of the wave-tube by using fast Fourier trans-
formation [14].
To separate the airway and tissue mechanics, a model
containing a frequency-independent resistance (Raw)
and inertance (Iaw) in series with a constant-phase tissue
model [16] including tissue damping (G) and elastance
(H) was fitted to the Zrs spectra by minimizing the dif-
ferences between the measured and modelled impedance
values:
Zrs ¼ Raw þ jωIaw þ G−jHð Þ=ωα
where j is the imaginary unit, ω is the angular frequency
(2πf ) andα =2/π arctan(H/G). When this model is fitted
to Zrs spectra, the parameter Raw is primarily related to
the overall airway geometry, as the contribution of the
chest wall to the frequency-independent Newtonian re-
sistance is minor [17]. Similarly, the inertia of the gas in
the airways predominates in the parameter Iaw [17]. The
equivalent dose causing a 50% increase in Raw (ED50)
was calculated in each rat by linear interpolation. Fol-
lowing these measurements, pulmonary arterial pressure
was measured as described below. The specific airway
resistance (SRaw) was calculated as Raw*EELV.
Measurement of pulmonary haemodynamics
The pulmonary arterial pressure was measured by introdu-
cing a small catheter (polyethylene tubing, ID 0.88 mm, Por-
tex, Hythe, GB) into the pulmonary artery via the jugular
vein before the animals were sacrificed. Since the diastolic
pulmonary arterial pressure (PapD) reflects the left atrial
pressure and thus the end-diastolic left ventricular pressure,
we used this parameter to express the haemodynamic con-
sequence of a LVD. Because of the technical demands of this
manoeuvre for successful introduction of the miniature
catheter in rats, this measurement proved technically ac-
ceptable only in subgroups of the main study groups, involv-
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challenges
The experimental protocol included the follow-up of the
same animals through the 8-week study period by perfor-
ming the identical procedure at weeks 0 and 8 (Figure 1).
On each occasion, the rats were anaesthetized and pre-
pared as detailed above. EELV was first measured while
the rats were breathing spontaneously. A femoral vein
was then cannulated for drug delivery. When stable
haemodynamic and respiratory mechanical conditions had
been reached, we recorded a set of Zrs data including
the collection of 4-6 6-s data epochs under the baseline
conditions. Increasing doses of iv methacholine (MCh)
were then administered at doses of 2, 6 and 18 μg/kg/
min. 3-5 Zrs recordings were made at each infusion rate
during the steady-state bronchoconstriction that devel-
oped, usually 3-5 min after the onset of MCh. Following
these measurements, PapD was measured as described
above.
Statistical analyses
The scatters in the parameters were expressed by the SD
values. The Kolmogorov-Smirnov test was used to check
data for normality. Two-way repeated measures analysis
of variances (ANOVA), with variables of treatment
(i.e. the protocol groups) and measurement condition (i.e.
weeks 0 and 8), was used to evaluate the effects of the vari-
ous types of medication on the respiratory mechanical para-
meters and EELV and the alterations in lung responsiveness
to the constrictor challenge. The pulmonary haemodynamic
differences between the groups were tested by using one-
way ANOVA. Pairwise comparisons were performed by
means of Student-Newman-Keuls multiple comparison pro-
cedures. The Pearson correlation test was used to assess the
strength of associations between variables. Statistical tests
were carried out with the significance level set at p < 0.05.
Results
There was no significant difference in body weight be-
tween the protocol groups at the beginning of the study
(ranging from 308 ± 56 g to 314 ± 62 g, p = 0.71). Eight
weeks later, however, the body weight of the animals in
Group IE (463 ± 9 g) was significantly lower than those
of the rats in Groups C (518 ± 27 g, p < 0.001), I (498 ±
32 g, p = 0.014) or ID (498 ± 30 g, p = 0.014). The
changes in the breathing frequency during EELV mea-
surements reflected these developmental changes with
decreases from 66 ± 22, 74 ± 13, 78 ± 20 and 74 ± 16
breath/min at week 0 (p = 0.6) to 39 ± 8, 44 ± 14, 43 ± 18
and 54 ± 23 breath/min at week 8 (p = 0.29) in Groups
C, I, ID and IE, respectively.
The baseline values of the airway and respiratory tissue
mechanical parameters exhibited significant decreases
(p < 0.001 for all) between the two study occasions (Figure 2).We found that none of the parameters displayed a signifi-
cant difference between the study groups under the baseline
condition (p = 0.16, 0.87 and 0.38 for Raw, G and H, respect-
ively). The lack of any significant interaction between the
measurement time and the protocol group demonstrated
that the induction of the LVD and its treatments had no sig-
nificant effects on the changes in the mechanical parameters
(p = 0.52, 0.25 and 0.54 for Raw, G and H, respectively).
EELV and the baseline SRaw increased significantly
(p < 0.001 for both) in all groups by the end of the 8-week
study period (Figure 3). The percentage relative increase in
EELV after 8 weeks was significantly higher in the Group ID
(118 ± 48%) thank in Group C (75 ± 30%, p = 0.048), and
there was a tendency for an excessive EELV increase in
group I (145 ± 107%, p = 0.09). Mild but statistically signifi-
cantly more pronounced elevation in SRaw were observed
in the rats of Group IE (p = 0.047) by the end of the 8-week
study period (Figure 3).
MCh provocations induced a dose-dependent broncho-
constriction in all groups (p < 0.001, Figure 4). No change in
airway responsiveness was detected in Group C (p = 0.7),
whereas the induction of a LVD led to the development of
BHR in the rats in Group I (p = 0.02), as illustrated by the
significant upward shift in the dose–response curve. Each of
the treatment strategies exerted a protective effect against
this hyperresponsiveness to MCh, with abolition of the dif-
ference in airway responsiveness in Groups ID (p = 0.3 week
0 vs. week 8) and IE (p = 0.65 week 0 vs. week 8). These
findings were reflected in the lack of significant change in
ED50 in Groups C (9.2 ± 1.9 vs. 10.2 ± 4.4 μg/kg/min, p =
0.65), ID (9.5 ± 3.6 vs. 10.7 ± 4.7 μg/kg/min, p = 0.33) and IE
(10.6 ± 2.1 vs. 9.8 ± 3.5 μg/kg/min, p = 0.56), whereas it
decreased markedly in the rats in Group I (10.0 ± 2.5 vs. 6.9
± 2.5 μg/kg/min, p = 0.006).
The induction of the LVD increased PpaD in all groups
where pulmonary hypertension was generated by coron-
ary ischaemia (Figure 5), with variable but significant
elevations in Groups I (p = 0.004), ID (p = 0.013) and IE
(p = 0.006).
The analyses of the associations between the changes in
pulmonary haemodynamics and respiratory mechanics
revealed no significant correlations between the magni-
tude of pulmonary haemodynamic changes expressed as
PapD and the alterations in lung responsiveness expressed
as the difference in ED50 between weeks 0 and 8
(R = 0.097, p = 0.61, Figure 6). Furthermore, no significant
correlation was observed between PapD and the 8-week
changes in EELV (R = 0.033, p = 0.86), while there was a
tendency to a strong association between PapD and the 8-
week changes in Raw (R = -0.35, p = 0.06).
Discussion
Various treatment strategies are applied in the pres-
ence of a LVD in order to enhance the cardiac output
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Figure 2 Changes in the baseline values of the respiratory mechanical parameters obtained by forced oscillation before (W0) and 8 weeks after
the induction of a LVD (W8) in rats that underwent sham surgery (Group C), and in rats with a LVD without subsequent treatment (Group I) or
supplemented with treatment with calcium channel (Group ID) or ACE blockers (Group IE). Raw: airway resistance, G: tissue damping, H: tissue
elastance. Thin dashed lines with small symbols: individual animals; thick lines with large symbols: group means. *: p < 0.05 W0 vs. W8.
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Figure 3 Changes in the end-expiratory lung volume (EELV), its value normalized to body weight (Normalized EELV) and the specific
airway resistance (SRaw) before (W0) and 8 weeks after LVD induction (W8) in rats that underwent sham surgery (Group C), and in rats
with a LVD without subsequent treatment (Group I) or supplemented with treatment with calcium channel (Group ID) or ACE blockers
(Group IE). Thin dashed lines with small symbols: individual animals; thick lines with large symbols: group means. *: p < 0.05 W0 vs. W8.
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Figure 4 Alterations in lung responsiveness expressed as changes in airway resistance during increasing doses of methacholine (MCh
2, 6 and 18 μg/kg/min). Data points were obtained before (W0) and 8 weeks after LVD induction (W8) in rats that underwent sham surgery
(Group C), and in rats with a LVD without subsequent treatment (Group I) or supplemented with treatment with calcium channel (Group ID) or
ACE blockers (Group IE). Thin dashed lines with small symbols: individual animals; thick lines with large symbols: group means. *: p < 0.05 W0 vs.
W8; #: p < 0.05 vs. the corresponding data point obtained in Group C.
Petak et al. Respiratory Research 2012, 13:114 Page 6 of 9
http://respiratory-research.com/content/13/1/114by optimizing the preload of the left ventricle and sub-
sequently decreasing the pulmonary vascular engorge-
ment or by decreasing the systemic vascular resistance.
In the present study, we investigated the abilities of
treatments considered against a LVD to protect the


















Figure 5 Diastolic pulmonary arterial pressures in the rats
involved in the different groups. Group C: control group that
underwent sham surgery, Group I: rats with a LVD without further
treatment, Group ID: rats with a LVD treated with a calcium channel
blocker (diltiazem). Group IE: rats with a LVD treated with an ACE
blocker (enelapril). *: p < 0.05 vs. the data obtained in Group C.heart failure. We applied a well-validated animal model
of coronary ischaemia to induce a sustained elevation
of left atrial pressure, leading to postcapillary PHT and
the subsequent development of BHR. Under this
pathophysiological condition, both treatment strategies
(based on blockade either of the rennin-angiotensin
pathway supplemented with diuretics or of the cal-
cium channels) abolished the enhanced lung respon-
siveness to exogenous constrictor stimuli without
affecting the lung volume increase. Examination of
the relationships between the pulmonary haemo-
dynamic and lung functional changes revealed that the
diastolic Pap level and the magnitude of the lung re-
sponsiveness were dissociated.
In agreement with the earlier reported findings
[11,18], the induction of left ventricular myocardial is-
chaemia led consistently to postcapillary PHT, as proved
by the marked elevations in PapD in the present study.
The achievement of more detailed experimentation to
characterize the altered pulmonary haemodynamics in
the present study was complicated by the small size of
the model animal and the lack of a catheter-tip balloon
facilitating its introduction into the pulmonary artery.
This technical drawback was the main reason for the
availability of a technically acceptable PapD recording in
only about two-thirds of the rats, which agrees well with
the previous success rate in this species when a similar
technique was used [11,19]. Due to the technically chal-
lenging nature of the surgical preparation of LVD, one
control group of rats with LVD was assessed (Group I)
instead of involving separate control groups of rats with
ip saline injections or oral placebo treatment. Since the

































































Figure 6 Relationships between the diastolic pulmonary
arterial pressures (PpaD) measured 8 weeks after LVD induction
and the changes in lung responsiveness to MCh (ED50) in the
end-expiratory lung volume (EELV) and in the airway resistance
(Raw). Data points were obtained in rats that underwent sham
surgery (Group C), and in rats with a LVD without subsequent
treatment (Group I) or supplemented with treatment with calcium
channel (Group ID) or ACE blockers (Group IE).
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necessitated only mild restrains of the animals for short
period of times, the interventions related to the treat-
ments per se were not likely to bias our findings.
In the presence of a LVD, the systematic enhancement of
the airway responsiveness to exogenous constrictor stimuli
as a hallmark feature of BHR was confirmed in the present
study [11]. In complete agreement with a previous observa-
tion [20], there was no significant correlation between the
degree of lung congestion estimated from PapD and the se-
verity of BHR (Figure 6), confirming that a more severe
pulmonary vascular congestion after a LVD does not neces-
sarily involve a more severe BHR. This consistent finding
demonstrates that the enhanced MCh responsiveness fol-
lowing a sustained LVD is not directly related to the altered
geometry of the congested pulmonary vessels. Rather, LVD
may trigger a cascade mechanism via a release of numerous
broncho- and vasoactive mediators, causing the develop-
ment of vascular remodelling and subsequent BHR.
It is noteworthy that BHR was observed previously on
use of a constrictor challenge with serotonin [11] and
this feature was fully reproduced in the present study by
applying MCh as a provocation agonist. Since serotonin
and MCh induce bronchoconstriction by activating dif-
ferent receptors, with the former acting on the muscar-
inic and the latter stimulating the 5-hydroxytryptamine
receptors, the consistent detection of BHR demonstrates
that, in the presence of a sustained LVD, the enhanced
lung responsiveness is independent of the receptor sub-
type via which the different agonists exert their broncho-
constrictive potentials.
While all respiratory mechanical parameters at the
baseline level exhibited marked decreases in the 8-week
study period, due to the somatic growth (Figure 2), nei-
ther the presence of the LVD nor the treatments affected
them significantly. This finding agrees with the previous
experimental data indicative of a lack of change in the
baseline values of airway or respiratory tissue mechanics
following a sustained pre- [19,21] or postcapillary PHT
[11]. Furthermore, this result is in line with previous
clinical observations that demonstrated no significant
effects of a LVD on the basal airway [22] or respiratory
[23] resistance. The present study is the first to demon-
strate a follow-up in the lung volume changes before and
after a sustained LVD. The changes observed in EELV and
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be explained almost fully by the lung growth (Figure 3,
top). Since the EELV values were corrected for the thermal
characteristics of the plethysmograph, the uniform altera-
tions in the breathing rate in the protocol groups was not
likely to bias our estimates [13]. The strong tendency for
excessive increases in the EELV in the rats with a LVD
may be attributed to the involvement of the autonomous
nervous system in the presence of hypoxia [12,24] that
might have been present after the induction of LVD [1].
The use of calcium channel blockers in the presence
of LVD has been challenged in clinical practice in the
past decade [25]. However, among the calcium antago-
nists, diltiazem was demonstrated to exhibit the best
profile without a significant negative inotropic effect and
an improvement in cardiac function following coronary
ischaemia [26]. Our findings suggest that diltiazem did
not inhibit the pulmonary vascular engorgement, as
revealed by the preservation of a high PapD in the majority
of the rats treated for 8 weeks (Figure 5). Conversely, diltia-
zem prevented the development of BHR (Figure 4) by
diminishing the bronchoconstriction at all doses of MCh.
This beneficial effect is most probably due to the effect of
diltiazem on the calcium channels, with a consequent de-
crease in the Ca2+ influx into the smooth muscle cells.
Since Ca2+ is essential for the contractility of the airway
smooth muscle cell, diltiazem may exert its potential pro-
tection effect via this cellular mechanism [27].
A LVD following coronary ischaemia leads to a decrease
in cardiac output and stimulates the renin-angiotensin-
aldosterone pathway, which then results in renal sodium
and water retention, contributing further to the overload,
and hence increasing the preload of the left ventricle
[28,29]. A combination of enalapril and diuretics is there-
fore the first-line treatment of cardiac failure, through in-
hibition of this mechanism, leading to optimization of the
preload of the left ventricle and a subsequent decrease in
the pulmonary venous pressure. In agreement with the lit-
erature, the 8-week treatment with enalapril slightly
retarded the body weight gain most probably by affecting
the metabolic homeostasis [30]. Furthermore, this treat-
ment proved to be beneficial in the majority of animals,
with a decrease in PapD, though some rats still exhibited a
very high pulmonary venous pressure (Figure 5). Despite
this fairly diverse pulmonary vascular effect, enalapril
exhibited a uniform beneficial effect on the respiratory
mechanics and airway responsiveness. It is noteworthy
that this treatment slightly but statistically significantly
elevated the baseline value of SRaw, which may be related
to the irritating properties of enalapril on the airways, oc-
casionally causing mild airway obstruction [31]. As
regards the potential of ACE inhibition to affect BHR,
there have been conflicting findings, with some authors
promoting its beneficial profile [32,33], others reportingno change in lung reactivity [34] and some even demon-
strating a worsening airway responsiveness [35,36]. Our
results are in line with those suggesting that ACE inhib-
ition with enalapril may counterbalance the constrictor
effect of angiotensin on the airway smooth muscle and
may blunt the BHR observed following cholinergic
stimulation with MCh [32]. Since the level of angioten-
sin is expected to increase following a LVD, the block-
ade of this pathway may be responsible for this
beneficial pulmonary profile observed in the present
study. Besides this potential beneficial profile of enala-
pril, the supplemental administration of furosemide
may further contribute to the inhibition of BHR, since
this diuretics was proved to decrease airway responsive-
ness in humans [37] and in rodents [38]. This effect
may be related to ease of the mechanical load exerted
by the congested pulmonary capillaries on the airways
and/or to the modulation of the neurotransmission [37].
Summary and conclusions
Surgical induction of coronary ischaemia in the present
study confirmed that a sustained increase in left atrial
pressure and subsequently in the pulmonary vasculature
enhances the airway responsiveness to exogenous con-
strictor stimuli and suggested an elevation of static lung
volume. The pathogenesis of this phenomenon was effect-
ively prevented by blocking the calcium channels follow-
ing the insult and by treating the adverse neurohumoral
consequences of the LVD by counteracting the adverse
vascular effect of the angiotensin pathway. Relating the ef-
ficiency of these treatments on the lung responsiveness
and the pulmonary haemodynamics revealed that both
strategies exhibit more consistent benefit against airway
hyperresponsiveness due to pulmonary vascular engorge-
ment than on the rather variable profile on the lung vas-
culature. The lack of a close association between the
severity of BHR and the degree of lung congestion sug-
gests that broncho- and vasoactive mediators were
involved rather than alterations in the geometry of the
congested pulmonary vessels. The abolition of airway
symptoms in patients with a LVD following these treat-
ment strategies is therefore anticipated.
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